Markus Peck‐Radosavljevic

机构：Klinikum Klagenfurt · ORCID：0000-0002-0597-2728

发表论文 763 篇 · 总被引 27220 次 · h-index 85

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 531)
• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 76)
• Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 73)
• Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV) (2023 · Wiener klinische Wochenschrift · 被引 69)
• Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab (2024 · JHEP Reports · 被引 11)
• Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma (2023 · Clinical Gastroenterology and Hepatology · 被引 10)